THE MEDFIELD PHARMA CASE: FIRM VALUATION AND ETHICAL CONSIDERATIONS OF REFORMULATION Understand that the Medfield case has 2 major problems: 1) Firm Valuation – Impact of Patent Loss and...

1 answer below »

THE MEDFIELD PHARMA CASE: FIRM VALUATION AND ETHICAL CONSIDERATIONS OF REFORMULATION




Understand that the Medfield case has 2 major problems: 1) Firm Valuation – Impact of Patent Loss and Reformulation; 2) Ethical Considerations – How to Ensure Patients and third-party payees are not hurt




Organize your paper around the case questions. Use them as an organizing device. This will benefit you in several ways: 1) provide a framework for constructing your paper; 2) ensure I (your reader) understand exactly what question you are answering; and 3) ensure you answer every question.




Use examples from Pfizer, AstraZeneca and other firms in EXHIBIT 3 to substantiate your thought.






  1. What is the current value of Medfield as a company? Use the exhibit 4 spreadsheet to calculate the NPV of Medfield. Compare this result to the offer price and provide your reasoning for the difference.




  2. If we consider the sale of Medfield as the sale of existing assets how does the elimination of R&D, investment in future assets, change the valuation of Medfield? (Using the exhibit 4 spreadsheet distinguish between the NPV value of existing products and R&D)




  3. What is the value that would be created by a reformulation? Complete and explain the table below.



















































































































































































































































































































































































































































2011



2012



2013



2014



2015



2016



2017



2018



2019





2020



2021



2022





2023



2024



Incremental Research



35



35







































Incremental Special Marketing



25



25



25



25



25











































































Growth






2%



-50%



2%



2%



2%



2%



2%



2%





2%



2%



-50%





-50%



-50%



New Sales



214.77










































Marginal Sales (New Sales – Original Sales



0.00























































































New Cost of Sales



49.40










































Marginal Cost of Sales



0.00























































































New Direct Marketing



57.99










































Old Direct Marketing



57.99



59.15



29.57



14.79



7.39



0



0



0



0





0



0



0





0



0



Marginal Direct Marketing



0.00























































































New G&A



8.59










































Old G&A



8.59



8.76



4.38



2.19



1.10



0



0



0



0





0



0



0





0



0



Marginal G&A



0.00
































































































Marginal Cash Flow pre Tax



(60.00)







































29.52



14.76



7.38



Marginal NOPAT



(40.80)







































20.07



10.04



5.02

























































NPV
















































































































  1. What factors explain the value created from the reformulation for Fleximat?




  2. Who reaps the financial benefits?




  3. Who bears the financial costs?






ONLY ANSWER ONE OF THE QUESTION 7’S:


IF YOU SUPPORT REFORMULATION:






  1. What facts would change your mind and cause you to recommend against reformulation?




IF YOU ARE AGAINST REFORMULATION


7. Under what conditions might you be in favor of reformulation?






  1. How would you change your thinking if Medfield’s reformulation approach were more substantive (e.g. drug works faster, works longer) than cosmetic?




  2. Could Medfield use the extra value created by the reformulation to generate new and helpful products?




  3. When you consider Medfield’s stakeholders, what are the key issues for each of the following:







    1. Shareholders of Medfield




    2. Patients using the drug




    3. Third-party payees (Medicare, private insurance companies, etc.)




    4. Government




    5. Employees of Medfield




    6. Physicians







  1. What ethical issues need to be considered in making a reformulation decision? Which are more pressing? Reference the ethics concepts discussed earlier in the semester, include at least one of the Right vs. Wrong explanations presented: Consequences, Duty, or Virtues. Use external references sources to support your discussion of the ethical issues.




  2. What should Susan Johnson do? Explain your choice of a, b, c, or d. If you have another approach, discuss it here.







    1. Don’t pursue the reformulation, but accept takeover offer




    2. Initiate the reformulation and accept the offer




    3. Refuse the offer but initiate reformulation




    4. Refuse the offer and not reformulate







Your Turnitin Score needs to be 0-30% tops. Try to get it down there. If it is higher, I will read your paper, and see why the score is high but your grade will reflect the score.




REFERENCES MUST BE IN ALPHABETICAL ORDER. NAKED URLS ARE NOT ACCEPTABLE




APA conventions for citing and referencing:




https://owl.purdue.edu/owl/research_and_citation/apa_style/apa_formatting_and_style_guide/general_format.html//owl.purdue.



Answered Same DayDec 13, 2021

Answer To: THE MEDFIELD PHARMA CASE: FIRM VALUATION AND ETHICAL CONSIDERATIONS OF REFORMULATION Understand that...

Sameeksha answered on Dec 17 2021
139 Votes
THE MEDFIELD PHARMA CASE:
FIRM VALUATION AND ETHICAL CONSIDERATIONS OF REFORMULATION
Table of Contents
Table of Contents    1
Introduction    2
1. Valuation of Medfield    2
2. Factors justifying value created from the reformulation for Fleximat    0
Cost Benefit Analysis of Reformulation    0
3. Conditions favouring Reformulation    0

4. Usage of extra value created by the reformulation    1
5. Key issues for Medfield’s stakeholder:    1
6. Ethical issues need to be considered in making a reformulation decision    1
7. Recommendation    2
References    3
Annexures    4
1. Annual Income Statement    4
2. Balance Sheet    5
3. Financial Forecast Based on Existing Products    6
4. Drug Reformulation Methods    6
Introduction
Founder and CEO of Medfield Pharmaceuticals, Susan Johnson, started the business 20 years back to bring wellness to people’s life. There are 3 major drugs of Medfield of which Fleximat is going to off patent in coming 2 years. Medfield has the option to either accept the takeover offer worth $750 million or reformulate the drug Fleximat which has 2 years due to patent going off.
1. Valuation of Medfield
Medfield has the option to reformulate Fleximat (highest contributor to revenue) or takeover at $750 million and to better understand both the options and take a decision it is important to calculate the valuation of Medfield by calculating NPVs of both the options individually.
For calculating the current value of Medfield under both the options it is important to undertsand the product profile and its financials (annexures 1 to 3).
    Product
    Revenue Contribution
    Patent
    Fleximat
    64%
    2
    Lodamadal
    12%
     
    Orsamporph
    24%
    8
    Reximet
    Due to start
    Due to start
Further base on the past financials and the future growth projections provided following assumptions are drawn.
    Assumptions (except discount rate proportion to sales)
    Revenue Contribution
    Cost of Sales
    23%
    Research
    19%
    Direct marketing
    27%
    General Administrative
    4%
    Tax rate
    32%
    Discount Rate
    8.5%
Further the NPV of Medfield considering all the 4 products is calculated based on the financials provided in Annexure 1 to 3 as shown in the table below. The NPV is 439.11
2
Option 1- Takeover offer analysis the Current market Valuation
Table: 1; Source; Made by Student. (2019)
Option 2- Reformulation of Fleximat
In case if Medfield approves the reformulation of Fleximat, the following table shows the changes in Revenue, Expenses and NPV.
The NPV in this case will come to $424.37 which is still less than the takeover offer of $750
Thus, considering the current market valuation and NPV after reformulation, takeover seems to be a better options on the financial grounds.
Table; 2; Source; Made by Student (2019)
2. Factors justifying value created from the reformulation for Fleximat
Fleximat reformulation is a strategic decision to be taken considering the benefits and costs that it will bring in to the Medfield. There are various factors that affect the post reformulation valuation of the Medfield (Murteira, et al., 2013). This includes the additional or incremental cost Fleximat will require for reformulation. Susan was looking for relaunching Fleximat using an extensive marketing and research efforts. All this was...
SOLUTION.PDF

Answer To This Question Is Available To Download

Related Questions & Answers

More Questions »

Submit New Assignment

Copy and Paste Your Assignment Here